104 filings
Page 2 of 6
6-K
6nhubs fpq
3 Jul 23
Current report (foreign)
4:15pm
6-K
4kk95o6cd6q8j wp1
22 Jun 23
Aslan Pharmaceuticals Enters into a Strategic Licensing Deal with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab In Japan
8:32am
6-K
ml47 0pys
28 Apr 23
Aslan Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:29am
6-K
9d751tgd5zn3r75
24 Mar 23
Aslan Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
7:02am
6-K
lwd891fu7iqs7nazr31k
10 Mar 23
Aslan Pharmaceuticals Announces Plan to Implement Ads Ratio Change
7:30am
6-K
xkj n3hslbna3
24 Feb 23
Unit Purchase Agreement
10:27am
6-K
c0ncyjj25vx m55nji37
31 Jan 23
Current report (foreign)
6:02am
6-K
38d2m3
4 Jan 23
Current report (foreign)
6:02am
6-K
wh30zkvbw31h2wgxabj
21 Dec 22
Current report (foreign)
6:03am
6-K
z6n0b oq8
28 Oct 22
Aslan Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:01am
6-K
kpud2b2 gdq
28 Sep 22
Current report (foreign)
9:01am
6-K
bu1c7gcz69
14 Sep 22
Current report (foreign)
7:45am
6-K
asa 3lisry7vo6e
13 Sep 22
Amendment No. 1 to the Open Market Sale Agreementsm
4:31pm
6-K
7t6gl
8 Sep 22
Current report (foreign)
7:01am
6-K
grt2tjfrjjsh
12 Aug 22
Aslan Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
6:54am
6-K
n2lb0v6a feigpa
27 Apr 22
Aslan Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
7:00am
6-K
vi9s0u8c
1 Apr 22
Aslan Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
5:00pm
6-K
mp1ve3
25 Mar 22
Aslan Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
7:05am
6-K
zvoiap
15 Mar 22
Aslan Pharmaceuticals Appoints Dermatology Veteran DR Alex Kaoukhov As Chief Medical Officer
7:05am
6-K
n0jm4go7
21 Jan 22
Current report (foreign)
7:29am